Guest Blogs - Page 2 of 45 - Express Pharma

Beyond the PDF: Why biopharma’s communication must catch up with Its science

The high cost of compromise: Why patient safety must come first

Pharma tariff bombshell: Navigating challenges, building resilience

Cell therapy’s next chapter: Industry embraces in-vivo innovation

Driving innovation in India’s pharma R&D through cell and gene therapy

Patent Rule Amendments 2024: Who gained who lost in amendment of FORM 27?

GST 2.0 is a tailwind for India’s Nutraceuticals

The myth of drug traceability in India

Nostalgia or euphoria of past employment

Pharma outsourcing trends 2025: Partnership, precision, and resilience